Perspective Therapeutics wins EU orphan drug status for [212Pb]VMT-α-NET in GEP-NETs

Reuters2026/07/28 10:35

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

European Commission granted orphan medicinal product designation for Perspective Therapeutics’ [212Pb]VMT-α-NET in gastroenteropancreatic neuroendocrine tumors.
Decision followed a positive opinion from the EMA’s Committee for Orphan Medicinal Products.
Status may offer EU development incentives, including fee reductions, protocol support, and up to 10 years of market exclusivity if approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Perspective Therapeutics wins EU orphan drug status for [212Pb]VMT-α-NET in GEP-NETs

You may also like

Crypto prices